| Opening Remarks |
09:00-09:10 |
| 1. |
Promise and challenges in cell-based immunotherapy |
09:10-10:50 |
| 1) |
NK cell immunotherapy in pancreatic cancer |
| |
?닿꼍誘?(怨좊젮?섎?) |
| 2) |
Reneration of cytotoxic T lymphocytes from pluripotent stem cells:
Development of "off-the-shelf T cells" for cancer immunotherapy |
| |
Hiroshi Kawamoto (Kyoto University) |
| 3) |
T-cell immunotherapy through engineering of TCR microclusters |
| |
?꾩갹??(愿묒＜怨쇳븰湲곗닠?? |
| 4) |
Discovery of a novel splenic subset of dendritic cells and harnessing their potential in immunotherapies |
| |
諛뺤콈洹?(?곗꽭?섎?) |
| |
|
|
| Coffee Break |
10:50-11:10 |
| 2. |
Quest for cancer vaccine: New development and application |
11:10-12:25 |
| 1) |
Therapeutic cancer vaccines |
| |
媛뺥깭??(嫄닿뎅?섎?) |
| 2) |
DC vaccine targeting neoantigens |
| |
Kazuhiro Kakimi (The University of Tokyo Hospital, Japan) |
| 3) |
The potential application of exosome inhibitor to improve immuno-oncology therapy |
| |
諛깅Ц李?(寃쎈턿?섎?) |
| |
|
|
| Luncheon Symposium (Presented by MSD) |
12:25-13:25 |
| |
Redefining survival with IO-TKI strategy in RCC |
| |
源�?명샇 (媛�?⑤┃?섎?) |
| |
|
|
| 3. |
Update on clinical immuno-oncology |
13:40-15:10 |
| 1) |
Insights for biology-based combinations to tackle advanced urologic cancer |
|
| |
源�李?(李⑥쓽?�) |
| 2) |
Neoadjuvant/Adjuvant immunotherapy in early lung cancer and breast cancer |
| |
?덊씗寃?(媛�泥쒖쓽?�) |
| 3) |
Peripheral blood biomarker related to immune check point inihibitor in non-small cell lung cancer |
| |
?덈챸二?(?깃퇏愿�?섎?) |
| |
|
|
| Coffee Break |
15:10-15:30 |
| 4. |
Combination of radiation and immunotherapy |
15:30-17:00 |
| 1) |
Novel radiotherapy and immunotherapy approaches for oligometastatic cancer |
| |
?μ???(?곗꽭?섎?) |
| 2) |
Exploring signals of synergy in clinical practice |
| |
?좎긽以� (?곗꽭?섎?) |
| 3) |
SART vs. CFRT in inducing the abscopal effect |
| |
諛뺤꽭愿?(?몄젣?섎?) |
| |
|
|
| Closing Remarks |
17:00-17:05 |